NSAID zaltoprofen improves the decrease in body weight in rodent sickness behavior models: proposed new applications...

Area of Science:

• Pharmacology
• Immunology
• Pathology

Background:

• Sickness behaviors, including anorexia and weight loss, are induced by cytokines during inflammation and infectious diseases.
• Cancer cachexia involves weight loss driven by sickness behaviors.
• Non-steroidal anti-inflammatory drugs (NSAIDs) show potential in managing cancer cachexia-related weight loss.

Purpose of the Study:

• To investigate the efficacy of NSAIDs in mitigating sickness behaviors and associated weight loss.
• To evaluate zaltoprofen's effect on weight loss in rodent models of hepatitis.

Main Methods:

• Utilized rodent models of sickness behavior, specifically concanavalin A (Con A)-induced mouse hepatitis and carbon tetrachloride-induced rat hepatitis.
• Administered zaltoprofen, a selective cyclooxygenase-2 inhibitor NSAID, to the animal models.
• Monitored sickness behaviors including anorexia, body weight changes, and locomotor activity.

Main Results:

• Zaltoprofen administration improved body weight loss in both Con A-treated mice and carbon tetrachloride-treated rats.
• Zaltoprofen demonstrated potent inhibition of cyclooxygenase-2 with reduced gastrointestinal side effects.
• Sickness behaviors such as anorexia, decreased body weight, and reduced locomotor activity were induced in the hepatitis models.

Conclusions:

• NSAIDs, particularly zaltoprofen, show promise for treating sickness behaviors and weight loss in conditions like cancer cachexia.
• Zaltoprofen's effectiveness in rodent models suggests its potential therapeutic application for managing cachexia-related symptoms.